The increasing global prevalence of dementia, a condition for which definitive preventative or curative treatments remain elusive for most forms, has amplified research efforts aimed at identifying modifiable risk factors that could mitigate its development. This urgent pursuit is underscored by projections indicating a significant rise in the number of individuals affected by dementia as populations age worldwide. A critical avenue of investigation, as highlighted by the Lancet Commission, centers on the potential to avert nearly half of all dementia cases by addressing fourteen distinct, alterable risk factors, with the management of cholesterol levels from midlife being a prominent consideration.
Specifically, the management of elevated low-density lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol, emerges as a key intervention point. Doctor Tummas Ternhamar of Copenhagen University Hospital in Denmark, who presented findings at the ESC Congress 2026, emphasized that "Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor." This concern is particularly pertinent for individuals diagnosed with type 2 diabetes, a condition frequently accompanied by high LDL-C levels and independently recognized as a contributing factor to cognitive decline and dementia.
Motivated by this confluence of risk factors, Doctor Ternhamar and his colleagues formulated a hypothesis: "We hypothesized that early initiation of LDL-C-lowering statins following type 2 diabetes diagnosis could be associated with a lower risk of dementia." To rigorously test this proposition, the research team employed a robust analytical framework designed to emulate a randomized controlled trial, thereby minimizing potential biases inherent in purely observational studies. This sophisticated methodology was applied to a substantial dataset derived from Danish national health registries.
The study encompassed an extensive cohort of 132,585 individuals who had received a diagnosis of type 2 diabetes between 2006 and 2019 and had no prior history of statin use. These participants were meticulously tracked through to the conclusion of 2021, with their medical histories scrutinized for any recorded diagnoses of all-cause dementia. To ascertain the impact of statin initiation timing, a clone-censor-weight design was implemented. This approach allowed for the comparison of dementia rates across three distinct groups: those who did not commence statin therapy within five years of their diabetes diagnosis; a group that initiated statins early, within one year of diagnosis; and a third group that began treatment at a later stage, between one and five years post-diagnosis.
Over a median follow-up period spanning 7.1 years, a total of 2.7% of the study participants were diagnosed with dementia. The analysis revealed a significant correlation between the timing of statin initiation and the subsequent risk of dementia. Individuals who commenced statin therapy within the first year following their type 2 diabetes diagnosis demonstrated a 15% reduction in their relative risk of developing dementia over a ten-year period, when compared to those who did not initiate statin treatment at all.
Even delaying the commencement of statin therapy yielded a discernible protective effect, albeit to a lesser extent. Those who began taking statins between one and five years after their diabetes diagnosis exhibited a 10% lower relative risk of dementia over the same ten-year timeframe. Importantly, these observed benefits were consistent across both male and female participants, suggesting a broadly applicable protective mechanism.
Doctor Ternhamar summarized the implications of these findings by stating, "In individuals developing type 2 diabetes, statins were associated with a lower risk of dementia, most pronounced in those with early initiation." He further commented on the current clinical landscape, noting, "Statins seem to be underused in patients with type 2 diabetes, despite their protective effects against cardiovascular disease." The research, therefore, "suggest[s] another potentially important reason to ensure that patients with type 2 diabetes and high LDL-C receive timely statin treatment."
While the study’s findings are compelling, it is crucial to acknowledge their observational nature, which precludes definitive claims of causation. The research does not definitively prove that statins directly prevent dementia; rather, it establishes a strong association between earlier statin use and a reduced incidence of the condition, suggesting potential benefits extending beyond their well-established role in cardiovascular health.
Professor Isabel Goncalves, a Member of the ESC Communication Committee, provided expert commentary on the study’s significance. She noted that individuals with type 2 diabetes are inherently at an elevated risk for dementia, and the current medical guidance already emphasizes cholesterol reduction to mitigate cardiovascular events. "This study suggests that starting statins soon after a type 2 diabetes diagnosis may also be linked to a modest reduction in dementia risk, with greater benefit than delaying treatment," she observed. Given the widespread availability and affordability of statins, Professor Goncalves deemed the findings "potentially important." However, she reiterated the caveat that, as an observational study, it "cannot prove that statins prevent dementia." Consequently, she concluded that the results "should therefore support further research and help inform discussions between patients and clinicians."
The research underpinning these insights received financial support from a consortium of esteemed organizations, including grants from the Danish Cardiovascular Academy, which is itself funded by the Novo Nordisk Foundation and The Danish Heart Foundation. Additional support was provided by Herlev and Gentofte Hospital, Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens Fond, Beckett fonden, Overlæge Johan Boserup og Lise Boserups legat, and Direktør Jakob Madsens og Hustru Olga Madsens fond, collectively enabling this important investigation into the multifaceted role of cholesterol management in the context of type 2 diabetes and neurodegenerative disease risk. The study’s contribution lies in its potential to refine clinical guidelines, encouraging earlier and more consistent statin prescription for diabetic patients, thereby potentially impacting long-term cognitive health outcomes. The observed gradient of benefit, with earlier intervention yielding greater risk reduction, highlights the critical importance of proactive and timely management of lipid profiles in this vulnerable patient population.
About the Author
